Nat. Rev. Clin. Oncol. doi: /nrclinonc

Slides:

Advertisements

Similar presentations

Looking Inside the Body

Advertisements

PET / CT in lymphoma Dr Bhuey Sharma Consultant Radiologist

Fig. 2. Arterial fluorodeoxyglucose (FDG) uptake related to atherosclerosis. On positron emission tomography (PET) coronal (A), PET/CT fusion coronal (B),

PET Criteria for Response Assessment After Completion of Therapy for Aggressive NHL and HL Definition of a positive PET scan (Visual assessment is adequate,

Figure 1. Suggested algorithm for locoregional lymph node staging in patients with non-metastatic NSCLC. CT, computed tomography; EBUS, endoscopic bronchial.

Staging of diffuse large B-cell lymphoma (DLBCL)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 3 Response after appearance of a new lesion

Figure 1 Concept of the therapeutic index

Figure 1 Carotid artery inflammation detected using 18F-FDG-PET

Figure 3 Risk-adapted and response-adapted

Figure 5 Schematic illustration of different clinical trial designs

Figure 2 New functional imaging techniques in lymphoma

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Intracranial targeting of high-grade gliomas

Figure 2 Three-step approach to the assessment and management

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Positron Emission Tomography in Non-Hodgkin's Lymphoma: Assessment of Chemotherapy With Fluorodeoxyglucose by Wolfgang Römer, Axel-R. Hanauske, Sibylle.

Figure 1 Chimeric antigen receptor (CAR) structures

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Identification of mucinous carcinoma

Yuji Nakamoto Clinical Lymphoma, Myeloma and Leukemia

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 CAR-T-cell design

Figure 2 The association between CD8+ T‑cell density of the tumour

Figure 1 Clinical case study

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Therapeutic targeting of the B-cell receptor (BCR)

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

chemotherapy for patients with MC versus those with AC

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 NIR fluorescence is more suitable for

Figure 1 The dynamic nature of resistance mechanisms can be

Figure 3 Summary of overall survival by Kaplan–Meier

Figure 2 Components of each transplantation platform

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Figure 2 Median monthly launch price of a new anticancer drug,

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 New PET radiotracers in lymphoma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Variations between planned and delivered doses of radiation

Metabolic response by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT). a) FDG PET/CT for patient 2 at baseline.

A, b, e, f) Computed tomography (CT) of the chest and c, d) positron emission tomography (PET) with 2-deoxy-2-[fluorine-18] fluoro-D-glucose (18F-FDG)

The role of positron emission tomography for non-small cell lung cancer Albert J. Chang, MD, PhD, Farrokh Dehdashti, MD, Jeffrey D. Bradley, MD Practical.

Frequency of lesions detected using CNS imaging (computed tomography [CT] and magnetic resonance imaging [MRI]) on patients with baylisascariasis (see.

Yasuo Miura, MD, PhD, Mitsuru Tsudo, MD, PhD Mayo Clinic Proceedings

Radiological evolution of acute respiratory distress syndrome over the first week in a 57-year-old male with non-Hodgkin’s lymphoma and H1N1 infection.

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 7 Overview of the methodological processes for

Figure 4 Radiogenomics analysis can reveal relationships

Figure 2 Radiomics in cardiology

Figure 1 Overview of the imaging biomarker roadmap

Positron emission tomography scan in the axial plane performed in June 2007 showing intense and homogeneous increased uptake of 18-fluorodeoxyglucose within.

Figure 3 Determination of the primary site

(A and B) Representative peaks using AKT primary antibody in normal lung and emphysema and tumour and matched normal lung, respectively. (A and B) Representative.

A) Positron emission tomography scan showing 18F-fluorodeoxyglucose uptake in the right supraclavicular, hilar and mediastinal lymph nodes and in the left.

CT (left of images) showing calcified areas and PET (right of images) scans showing increased FDG-PET metabolic activity in the mediastinal mass (A) and.

Figure FDG-PET, lymph node biopsy, and brain MRI

Algorithm for diagnosis and treatment of reported cases.

Figure 1 Gene-expression quantification methods

Non-invasive molecular imaging techniques may play a future role in the management of pulmonary hypertension. a) Positron emission tomography–computed.

Presentation transcript:

Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2017.78 Figure 1 Timeline depicting the development of clinicopathological classifications, staging, and response assessment guidelines, and radiographic techniques in lymphoma Figure 1 | Timeline depicting the development of clinicopathological classifications, staging, and response assessment guidelines, and radiographic techniques in lymphoma. Developments in pathological classification systems are shown in beige, developments in clinical or radiological classification systems are shown in blue, and developments in imaging technologies are shown in orange. Abbreviations: DLBCL, diffuse, large-B-cell lymphoma; FDG, fluorodeoxyglucose; IWG, International Working Group; LyRIC, Lymphoma Response to Immunomodulatory Therapy Criteria; MRI, magnetic resonance imaging; NHL, non-Hodgkin lymphoma; PET, positron-emission tomography; PETT, positron-emission transaxial tomography; REAL, revised European-American classification of lymphoid neoplasms; RECIL, Response Evaluation Criteria in Lymphoma; SUV, standard uptake value. *Denotes further discussion within article. Three categories within 'timeline': development in imaging technology, pathology classification system, clinical or radiological classification/staging system. Cunningham, J. et al. (2017) Evolution of lymphoma staging and response evaluation: current limitations and future directions Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2017.78